Who Paid My Doc
Bao Le
Interventional Cardiology College Station Medical Doctor
NPI 1588863898 CMS profile 343974
800 Scott & White Drive, College Station 76554
General payments
$12,768
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Bao Le of College Station is reported in the CMS Open Payments database as having received $12,768 across 435 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 65th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,755 | 75 | |
| 2024 | General | $2,216 | 116 | |
| 2023 | General | $4,891 | 119 | |
| 2022 | General | $2,310 | 80 | |
| 2021 | General | $1,150 | 26 | |
| 2020 | General | $196 | 10 | |
| 2019 | General | $251 | 9 |
Beside peers
- Bao Le
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Bao Le were reported at $1,755. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Bao Le | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $251 | $1,097 | $329–$3,048 | $163 |
| 2020 | $196 | $473 | $161–$1,480 | $114 |
| 2021 | $1,150 | $677 | $233–$1,827 | $132 |
| 2022 | $2,310 | $978 | $333–$2,724 | $149 |
| 2023 | $4,891 | $1,136 | $382–$2,986 | $160 |
| 2024 | $2,216 | $1,181 | $395–$3,326 | $164 |
| 2025 | $1,755 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 46 drugsPart D claims
5,375
Drug cost
$975,106
Branded share of claims
33.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 504 | $444,980 | |
| Multaq Dronedarone Hcl | Brand | 108 | $144,362 | |
| Xarelto Rivaroxaban | Brand | 115 | $118,830 | |
| Entresto Sacubitril/Valsartan | Brand | 85 | $86,372 | |
| Repatha Sureclick Evolocumab | Brand | 63 | $40,858 | |
| Jardiance Empagliflozin | Brand | 31 | $38,664 | |
| Ranolazine Er Ranolazine | Brand | 159 | $14,722 | |
| Flecainide Acetate | Generic | 222 | $13,304 | |
| Amiodarone Hcl | Generic | 299 | $9,592 | |
| Metoprolol Succinate | Generic | 312 | $6,636 |
The 10 drugs with the highest cost, of 46 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 99 billing codesPaid by Medicare
$208,686
Medicare patients
1,968
Services billed
4,378
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 54% | |
| Ischemic heart disease | 45% | |
| Atrial fibrillation | 37% | |
| Diabetes | 36% | |
| Heart failure | 33% | |
| Chronic kidney disease | 32% | |
| Depression | 27% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
435 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.